27th Jun 2024 12:46
27 June 2024
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Results of AGM
Roquefort Therapeutics (LSE:ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today, all resolutions proposed were duly passed.
The resolutions were put to shareholders via a poll, the results of which were as follows:
Resolution | Poll Results | Total Votes Withheld* | |||
For | Against | Total Votes Cast | |||
1 | Shares | 24,948,663 | - | 24,948,663 | - |
% | 100.00% | - | |||
2 | Shares | 24,943,456 | - | 24,943,456 | 5,191 |
% | 100.00% | - | |||
3 | Shares | 24,943,472 | - | 24,943,472 | 5,191 |
% | 100.00% | - | |||
4 | Shares | 20,529,178 | - | 20,529,178 | 4,419,485 |
% | 100.00% | - | |||
5 | Shares | 24,948,663 | - | 24,948,663 | - |
% | 100.00% | - | |||
6 | Shares | 24,948,663 | - | 24,948,663 | - |
% | 100.00% | - | |||
7 | Shares | 24,938,750 | 9,913 | 24,948,663 | - |
% | 99.96% | 0.04% | |||
8 | Shares | 24,938,730 | 9,933 | 24,948,663 | - |
% | 99.96% | 0.04% | |||
* Votes withheld are not counted in the calculation of the proportion of votes for and against a resolution.
The total number of ordinary shares in issue on 25 June 2024, the deadline for casting votes by proxy in advance of the AGM, was 129,149,998 shares. 19.3% of voting capital was instructed in respect of the resolutions put to the AGM.
Enquiries:
Roquefort Therapeutics plc | +44 (0)20 3918 8633 |
Stephen West (Chairman) / Ajan Reginald (CEO) | |
SP Angel Corporate Finance LLP (Broker) Jeff Keating / David Hignell / Vadim Alexandre | +44 (0) 20 3470 0470
|
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale | +44 (0)20 7466 5000
|
Peak IR (Investor Relations) Seb Wykeham | +33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.
Roquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· Midkine mRNA therapeutics with novel anti-cancer approach;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).
Related Shares:
Roquefort Thera